NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...
March 31, 2010 — A blood test may soon be able to identify which patients with multiple sclerosis will and will not respond to beta interferon. Only a reported two-thirds of patients with ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...
October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...
Disease activity despite interferon predicts poor MS outcomes In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes. HealthDay News — ...
LAS VEGAS, Sept. 26, 2023 /PRNewswire/ -- Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced today that it has reshaped the landscape of ...
The interferon market offers growth opportunities through advancements in formulation technologies and new delivery systems ...
MS typically appears in young adulthood, but 3% to 5% of cases have an onset in early childhood or adolescence. No disease-modifying therapies have FDA approval for persons younger than 18 years of ...
How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback